# Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine

> **NCT04361721** · — · UNKNOWN · sponsor: **IRCCS National Neurological Institute "C. Mondino" Foundation** · enrollment: 40 (estimated)

## Conditions studied

- Chronic Migraine

## Interventions

- **DRUG:** Erenumab

## Key facts

- **NCT ID:** NCT04361721
- **Lead sponsor:** IRCCS National Neurological Institute "C. Mondino" Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-15
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04361721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04361721, "Neurophysiological, Biomolecular and Psychological Aspects of Erenumab Treatment in Chronic Migraine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04361721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*